Document


UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C.  20549
 
 
FORM 8-K


CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): August 2, 2016


PFIZER INC.
(Exact name of registrant as specified in its charter)

Delaware
1-3619
13-5315170
(State or other
(Commission File
(I.R.S. Employer
jurisdiction of
(Number)
Identification No.)
incorporation)
 
 


235 East 42nd Street
10017
New York, New York
(Zip Code)
(Address of principal executive offices)


Registrant's telephone number, including area code:
(212) 733-2323

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))






Item 2.02 Results of Operations and Financial Condition

On August 2, 2016, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for the second quarter of 2016. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein.

The information furnished pursuant to this "Item 2.02 - Results of Operations and Financial Condition", including Exhibit 99, shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act") or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d)  Exhibits
 
Exhibit Number
 
Exhibit Description
 
 
 
Exhibit 99  -
 
Press Release of Pfizer Inc. dated August 2, 2016, reporting
Pfizer's financial results for the second quarter of 2016.


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 
PFIZER INC.
 
 
 
 
 
 
 
By:
/s/ Margaret M. Madden
 
 
Margaret M. Madden
 
 
Vice President and Corporate Secretary
 
 
Chief Governance Counsel
 
 
 
 
 
 
Dated: August 2, 2016
 
 





EXHIBIT INDEX

Exhibit No.
 
Description
 
 
 
99
 
Press Release of Pfizer Inc. dated
 
 
August 2, 2016, reporting Pfizer's financial
 
 
results for the second quarter of 2016.